Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | ILK | Q13418 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373464 | 1.00 | NPC1 (0.67) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL221431 | 0.80 | NPC1 (1.00) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2958852 | 0.80 | MIF (0.71) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL827403 | 0.77 | RAB9A (0.67) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30863871 | 0.76 | RAB9A (1.00) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL221183 | 0.76 | RAB9A (1.00) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28618681 | 0.75 | NPC1 (0.61) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL28205214 | 0.75 | RAB9A (0.64) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| Methane SCHEMBL28056221 | 0.75 | RAB9A (0.64) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL16859912 | 0.75 | RAB9A (0.64) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1958585-A | Ruthenium(II)complexes of second generation DNA molecule optical switch, and preparation method | BEIJING TEACHER S UNIV (CN) | 2007-05-09 | — | — | CN | claimed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| EP-2034997-A1 | ANTIBACTERIAL COMPOSITIONS | Prolysis Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
| CN-1958585-A | Ruthenium(II)complexes of second generation DNA molecule optical switch, and preparation method | BEIJING TEACHER S UNIV (CN) | 2007-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004221-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | NPC1 2581/4885RAB9A 3590/4885KDM4E 3843/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | NPC1 3471/4885RAB9A 3588/4885KDM4E 4304/4885 |
| US-20110263590-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | NPC1 2378/4885RAB9A 3558/4885KDM4E 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.